Marty Makary defends FDA drug approval decisions amid backlash
Updated
Updated · CNBC · May 5
Marty Makary defends FDA drug approval decisions amid backlash
11 articles · Updated · CNBC · May 5
In a CNBC interview, the FDA commissioner said three independent teams backed rejecting Replimune's melanoma candidate and denied the agency made "corrupt sweetheart deals."
Makary said he stands by FDA scientists and argued commissioners overruling reviewers has repeatedly proved disastrous, citing Aduhelm and a Covid-19 booster clearance for healthy young children.
His remarks follow intensifying criticism, including Bloomberg's report of turmoil inside the agency and a Wall Street Journal opinion piece questioning whether he has become a liability for President Donald Trump.
Amid pushes for faster drug approvals, how will the FDA avoid repeating past 'disasters' like Aduhelm?
With declining trust and staff, can the FDA's ambitious modernization initiatives actually succeed?